Role of cell-free DNA for predicting incidence and outcome of patients with ischemic stroke  

作　　者：Nusrath Fathima Sandhya Manorenj Sandeep Kumar Vishwakarma Aleem Ahmed Khan 

机构地区：[1]Central Laboratory for Stem Cell Research and Translational Medicine,Centre for Liver Research and Diagnostics,Deccan College of Medical Sciences,Hyderabad 500058,Telangana,India [2]Department of Neurology,Princess Esra Hospital,Deccan College of Medical Sciences,Hyderabad 500002,Telangana,India

出　　处：《World Journal of Neurology》2022年第1期1-9,共9页世界神经病学杂志

摘　　要：Early diagnosis and prognosis of ischemic stroke remains a critical challenge in clinical settings.A blood biomarker can be a promising quantitative tool to represent the clinical manifestations in ischemic stroke.Cell-free DNA(cfDNA)has recently turned out to be a popular circulating biomarker due to its potential relevance for diagnostic applications in a variety of disorders.Despite bright outlook of cfDNA in clinical applications,very less is known about its origin,composition,or function.Several recent studies have identified cell-derived mitochondrial components including mitochondrial DNA(mtDNA)in the extracellular spaces including blood and cerebrospinal fluid.However,the time course of alterations in plasma mtDNA concentrations in patients after an ischemic stroke is poorly understood.DNA is thought to be freed into the plasma shortly after the commencement of an ischemic stroke and then gradually decreased.However,the importance of cell-free mtDNA(cf-mtDNA)in ischemic stroke is still unknown.This review summarizes about the utility of biomarkers which has been standardized in clinical settings and role of cfDNA including cfmtDNA as a non-invasive potential biomarker of ischemic stroke.

关 键 词：Ischemic stroke MITOCHONDRIA Circulating cell-free DNA Plasma nucleic acid MORTALITY 

分 类 号：R74[医药卫生—神经病学与精神病学]